Updated projections of future vCJD deaths in the UK. by Ghani, Azra C et al.
Ghani, AC; Donnelly, CA; Ferguson, NM; Anderson, RM (2003) Up-
dated projections of future vCJD deaths in the UK. BMC Infect Dis,
3 (1). p. 4. ISSN 1471-2334
Downloaded from: http://researchonline.lshtm.ac.uk/13524/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
BioMed Central
Page 1 of 8
(page number not for citation purposes)
BMC Infectious Diseases
Open AccessResearch article
Updated projections of future vCJD deaths in the UK
Azra C Ghani*, Christl A Donnelly, Neil M Ferguson and Roy M Anderson
Address: Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College of Science, Technology and Medicine, Norfolk 
Place, London W2 1PG, UK
Email: Azra C Ghani* - a.ghani@imperial.ac.uk; Christl A Donnelly - c.donnelly@imperial.ac.uk; 
Neil M Ferguson - neil.ferguson@imperial.ac.uk; Roy M Anderson - roy.anderson@imperial.ac.uk
* Corresponding author    
Abstract
Background: Past projections of the future course of the vCJD epidemic in the UK have shown
considerable uncertainty, with wide confidence bounds. However, recent vCJD case data have
indicated a decrease in the annual incidence of deaths over the past two years.
Methods: A detailed survival model is fitted to the 121 vCJD deaths reported by the end of 2002
stratified by age and calendar time to obtain projections of future incidence. The model is
additionally fitted to recent results from a survey of appendix tissues.
Results: Our results show a substantial decrease in the uncertainty of the future course of the
primary epidemic in the susceptible genotype (MM-homozygous at codon 129 of the prion protein
gene), with a best estimate of 40 future deaths (95% prediction interval 9–540) based on fitting to
the vCJD case data alone. Additional fitting of the appendix data increases these estimates (best
estimate 100, 95% prediction interval 10–2,600) but remains lower than previous projections.
Conclusions: The primary vCJD epidemic in the known susceptible genotype in the UK appears
to be in decline.
Background
Since the announcement in March 1996 of a link between
variant Creutzfeldt-Jakob disease (vCJD) and bovine
spongiform encephalopathy (BSE) in cattle [1–3], there
has been considerable concern regarding the potential for
an epidemic of vCJD in the UK. To date, there have been
129 cases of vCJD reported in the UK, 7 of which remain
alive, with further cases reported in Ireland, France, Italy
and Canada. The recent decrease in deaths from vCJD in
the UK (17 cases in 2002, compared with 20 in 2001 and
28 in 2000) has prompted suggestions that any epidemic
of vCJD may indeed be much smaller than previously
feared. However, a recent survey of appendix tissues surgi-
cally removed between 1995 and 1999 showed a relative-
ly high prevalence of infection (1 positive sample in 8318
tissues) [4]. The latter result has raised concern over the
theoretical possibility of secondary transmission of vCJD
through surgical instruments or blood products [5,6].
In this paper we use a previously published model [7–12]
which relates estimated exposure to BSE-infected animals
to the vCJD case data to provide updated estimates and
prediction intervals for the short-and long-term course of
the primary vCJD epidemic in the UK, based on fitting to
vCJD deaths occurring to the end of 2002 and additional-
ly to the preliminary results from the survey of appendix
tissues.
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Methods
vCJD case data
Our updated analyses are based on the vCJD deaths occur-
ring to the end of December 2002. 121 deaths due to
vCJD had been diagnosed in the UK at this time (Figure 1)
http://www.doh.gov.uk/cjd/. The median age at onset of
symptoms is 26 years, and at death 28 years. The excess of
cases in younger individuals, compared with what would
have been expected in a random sample of the popula-
tion, suggests that younger individuals are either more
susceptible to infection, were exposed to a greater extent,
and/or have shorter incubation periods.
All cases tested to date are methionine (MM) homozygous
at codon 129 of the prion protein (PrP) gene [13]. Ap-
proximately 40% of the Caucasian population share this
genetic trait, with 13% valine homozygous and the re-
maining 47% heterozygous [14,15]. This genetic marker
is known to be important for other human Transmissible
Spongiform Encephalopathies (TSEs) including sporadic
CJD, iatrogenic CJD and kuru [16–18]. Whilst it is possi-
ble that other genotypes are also susceptible to vCJD (and
are either less susceptible than the MM genotype, or have
longer incubation periods), at present we have no cases
with which to constrain potential epidemic scenarios
among these other genotypes. Our model predictions are
therefore limited to the 40% of the population with the
MM genotype.
vCJD prevalence data
Preliminary results from testing appendix tissues for the
presence of abnormal PrP showed 1 positive appendix in
a sample of 8318 tissues [4]. The study was interrupted
with this result reported due to public health interest. The
majority of tissues tested (70%) were from the 20–29 age
group (with the remaining tissues restricted to the 10–50
age-group), and all were removed between 1995 and
1999. The data were analysed in batches of approximately
1000 samples to ensure anonymity. These data provide
the first estimate of the prevalence of asymptomatic infec-
tion in the population in the highest risk age-group. The
observation translates to an estimated detectable preva-
lence of 120 per million with 95% confidence interval
0.5–892 per million across the whole sample [4]. Howev-
er, interpretation of this result remains uncertain since it
is not known how sensitive the tests are over the course of
the incubation period, and whether a positive test is indic-
ative of an infected individual who will go on to develop
clinical disease. Whilst evidence of abnormal PrP has been
found in the appendix tissue of 19 out of 20 symptomatic
vCJD cases examined to date, as well as in 2 cases with ap-
pendixes removed prior to the onset of symptoms (3 and
4 years before death respectively), it was not found in the
appendix tissue of one patient removed 9 years prior to
the onset of symptoms [4,19]. We assume in our analyses
that the positive appendix arose from an MM-ho-
mozygous individual. If this is not the case, then projec-
tions for the MM-homozygous population are similar to
those obtained fitting to the case data alone (data not
shown). This would also indicate the potential for vCJD
cases to arise in other genotypes. However, since there
have not been any vCJD cases in these other genotypes to
date, it is difficult at present to project the potential scale
of any epidemic in these populations without making ad-
ditional untestable assumptions regarding these other
genotypes.
Statistical model
Full details of the model and fitting procedure, and de-
tailed sensitivity analyses, have previously been published
[7–12]. In brief, the probability that an individual dies
from clinical disease at time u and age a is given by
where S(u,a) is the survival probability (estimated from
UK census data), f(u) is the incubation period distribution
and β is the transmission coefficient. The time- and age-
dependent exposure hazard I(t,a) is given by
I(t, a) = v(t) g(a) ∫ Ω(z) w(z, t) dz.  (2)
Figure 1
Time series of 121 deaths from vCJD to the end of 2002 and 
95% Poisson confidence intervals.
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Here ν(t) is the effectiveness of control measures limiting
the bovine tissues allowed into the human food supply
(introduced mid-1989, and allowed to vary between 0
and 100% effective at reducing infectivity from this point
onwards), g(a) an age-dependent susceptibility/exposure
function, Ω(z) the relative infectiousness of bovines over
the course of their incubation period and w(z, t) the pro-
portion of cattle slaughtered at time t and time z away
from disease onset. The expected number of cases at time
u and age a is given by
c(u, a) = B(u - a) p(u, a)  (3)
where B(u - a) is the number of individuals born at time u
- a.
The model is fitted using maximum likelihood methods
to the time- and age-stratified vCJD deaths to the end of
2002 assuming that the data arise from a Poisson distribu-
tion. The individual cases are categorised into cells with at
least 5 observations in each cell. The best-fit point is that
which maximises the log likelihood (LnL), or equivalently
minimises
where x(u,a)are the observed cases at time u and age a. For
any model parameter, maximum likelihood confidence
intervals are obtained using likelihood ratio tests. Non-
linear optimisation techniques are used to fit the model
[20] using custom-written code. An intensive search of pa-
rameter space was performed, fitting from multiple start-
ing points and restricting parameter bounds, to ensure
that the best-fitting models were obtained.
Confidence intervals for the expected number of cases are
obtained by re-parameterising the model so that the ex-
pected number of cases between times u1 and u2, T(u1,u2),
is a model parameter. Combining equations 1–3, this is
given by:
For each proposed parameter set, equation (5) was solved
numerically to calculate β. If no solution was possible (for
example, if the proposed parameter set generated fewer
infections than the required epidemic size) then the pro-
posed parameter set was rejected. Prediction intervals are
obtained by adding Poisson variability to the confidence
intervals on the mean.
The model is additionally fitted to the prevalence data ob-
tained from a recent survey of appendix tissues. As the
study was interrupted (although not stopped) due to the
observation of a positive appendix, the 95% confidence
interval for the prevalence of infection in the population
is obtained from the likelihood term for a negative bino-
mial distribution. The reported results arise from 9 batch-
es with the positive result arising in the sixth batch. The
likelihood for this result (assuming a binomial distribu-
tion for the sixth batch conditional on having observed a
positive result and for the final three batches) is therefore
given by
where pi is the expected prevalence in batch i, ni is the
number of samples in batch i and xi is the number of pos-
itive appendixes in batch i. The expected prevalence at
time u in age-group a is given by
The expected prevalence in batch i is calculated from this
expression as the average prevalence in the age-group over
the period of time from which the samples were collected.
The model fit is then judged by the combination of the
Table 1: Projected future number of vCJD cases (MLE and 95% prediction interval) based on fitting to the vCJD case data alone and to 
the case data and prevalence data simultaneously.
vCJD case data alone vCJD case data and prevalence data simultaneously
2003–2005 20 (3–70) 28 (4–72)
2003–2008 40 (8–138) 60 (9–152)
2003–2080 40 (9–540) 100 (10–2,600)
Fit of the model (-2LnL) 18.7 26.6
Goodness-of-fit p-value 0.29 0.32
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Poisson likelihood fit to the cases and the likelihood fit to
the prevalence data given by equation (6).
Both the sensitivity and specificity of the diagnostic tests
at different incubation stages are unknown. We include an
additional parameter which specifies the proportion of
the incubation period for which the test is assumed to be
fully sensitive (working backwards from death), and as-
sume that the test has no sensitivity prior to this time. We
also assume the test is fully specific. Throughout this work
we assume that the positive appendix is from an MM-ho-
mozygous individual, but that the 8318 tissues are repre-
sentative of the general population (and hence 40% of
these tissues are from MM-homozygous individuals).
Parameters
Predictions from the model are sensitive to the estimates
of exposure to BSE-infected material, w(z,t) [9]. As in pre-
vious work, our analyses rely on estimates of exposure us-
ing data relating to BSE in cattle in Great Britain. However,
in our most recent analyses estimating exposure to pre-
clinical infected animals and unreported clinical cases we
have integrated the analysis of BSE clinical case data (up
to October 2002), screening data from apparently healthy
cattle and screening data from high risk' (casualty/fallen
stock) cattle. Previous work [21] details the methodologi-
cal extensions required to integrate the analysis of data on
clinical case incidence and results from the screening of
apparently healthy cattle to obtain estimates of case ascer-
tainment rates. Key to this is the incorporation of a mech-
anism underlying the apparent underascertainment of
cases indicated by the screening data. Two different possi-
ble mechanisms were examined: differential mortality of
BSE-infected animals and underreporting of clinical cases
[21]. The former is better able to explain the observed data
and involves animals close to clinical onset being more
likely than their age-matched peers to die on farm or be
slaughtered. Thus, differential mortality leads to a higher
infection prevalence in slaughtered animals than would
be expected naively from the clinical case incidence data
alone. Furthermore, animals slaughtered as a result of the
excess risk imposed by differential mortality, all in the lat-
est stages of incubating the disease, are allowed via a fitted
parameter to be more likely to be categorized as a high-
risk animal (either as fallen stock found dead on farms or
casualty animals). If the parameter is significant, then the
resulting prevalence of infection is greater in high-risk an-
imals than in other animals slaughtered as apparently
healthy.
The exposure estimates used here were obtained assuming
that diagnostic test sensitivity was 100% for the last 3
months of the incubation period but virtually 0% before
this and assuming that deaths due to differential mortality
were distributed over the 3 months of the incubation pe-
riod of infected animals (this is the differential mortality
pattern assumed in Donnelly et al. 2002 [21]). Further-
more, the diagnostic test was assumed to be 100% specific
in all animals.
Pathogenesis experiments in cattle have indicated that
BSE infectivity is most widely distributed in the carcass to-
wards the end of the incubation period [22,23]. We there-
fore model the relative infectiousness of cattle at different
stages of incubation assuming that infection increases ex-
ponentially towards the end of the incubation period [7].
Clinical BSE cases (including those reported prior to mid-
1988) are assumed to be as infectious as those pre-clinical
animals within 6 months of onset of disease. Predictions
are fairly insensitive to the parameters for this parametric
form.
In previous work, we explored a number of different par-
ametric forms for the age-dependent susceptibility/expo-
sure function, g(a) [9]. The best fitting distributional form
is a 3-parameter combined uniform distribution with
gamma-distributed tails, which in its limits is either the
uniform or gamma distribution.
The functional form of the incubation period distribution
is informed by patterns observed for other TSEs. In partic-
ular, for other human TSEs it is known that the incubation
period is long and highly variable [16,24,25]. For many
TSEs there is a minimum incubation period so that func-
tional forms must allow for the potential for a substantial
delay following infection until the onset of clinical symp-
toms of vCJD [26,27]. We use a modified form of the four-
parameter Generalised Lambda distribution [28] (with in-
verse CDF ). This
distribution is more flexible than distributions based on
standard functional forms (such as the Weibull, LogNor-
mal or Gamma distributions), and incorporates all of
these standard distributions as special cases.
Results
The revised projections for future numbers of cases in the
susceptible genotype arising from a primary epidemic (i.e.
from consumption of beef and beef products from infect-
ed animals) are shown in Table 1. Based on fitting to the
vCJD case data alone (which is comparable to previous
analyses [9,10]), the upper limit of the 95% prediction in-
terval (PI) for future cases has decreased from approxi-
mately 7,000 cases last year to just 540 cases.
Furthermore, the best estimate of future case numbers is
now relatively small (40 future cases), indicating that the
vCJD epidemic in this genotype appears to have peaked
and is now in decline. This decline is also reflected in the
short-term projections, with only 20 cases expected in the
next 2 years (95% PI 3–70) and 40 cases in the next 5
years (95% PI 8–138).
X p p p( ) ( ( ) )/= + + − −−λ λλ λ1 23 41 1
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If the model is additionally fitted to the prevalence data
obtained from the survey of appendix tissues, and it is as-
sumed that the positive appendix arose from an MM-ho-
mozygous individual who will go on to develop clinical
disease, projections of the magnitude of the primary epi-
demic are increased. In particular, the best estimate of fu-
ture cases is roughly doubled (from 40 to 100) whilst the
upper 95% prediction bound is substantially increased
from 540 cases to 2,600 cases (Table 1). Figure 2 shows
the likelihood profiles for the fit of the model to the vCJD
case and appendix data simultaneously and demonstrates
the inconsistency between the vCJD case data and the
prevalence data. The best fits to the vCJD case data are ob-
tained for small epidemic sizes. In contrast, much better
fits to the appendix data are obtained for larger epidemic
sizes. The simultaneous fit of the model to both data
sources is therefore a trade-off.
Addition of the appendix data to the model also affects
the estimated incubation period distribution (Table 2).
Figure 3 shows the maximum likelihood estimate (MLE)
of the incubation period distribution obtained by fitting
to the vCJD case data alone, and to the vCJD case and
prevalence data simultaneously. The addition of the prev-
alence data to the model increases the estimated mean in-
cubation period and results in a longer tail to the
distribution. In contrast, as the prevalence data are ob-
tained from the highest-risk age groups (10 to 30 years),
the addition of these data to the model does not affect the
MLE of age-dependent susceptibility/exposure (Figure 4),
which remains similar to that obtained in previous work
[9]. Our results continue to highlight that the young are
either more susceptible or were exposed to a greater ex-
tent. Recent studies of the consumption patterns of high-
risk beef products (including head meat and burgers)
[29,30] have been unable to explain this solely in terms of
exposure, suggesting that younger individuals may have
also been more susceptible to infection.
Figure 5 shows the likelihood profile for the mean incuba-
tion period. In contrast to analyses undertaken last year
[9], the data now allow a meaningful estimate of the mean
incubation period to be made. By fitting to the case data
alone, we estimate a mean incubation period of 12.6 years
(95% confidence interval 8–35 years) for the MM-geno-
type. Additionally fitting the model to the prevalence data
increases this mean to 16.7 years (95% confidence inter-
val 8–30 years). These estimates are greater than those ob-
tained for iatrogenic CJD (mean incubation period of 9–
10 years with an upper 95% confidence limit of 15–16
years [24]) as would be expected from animal experi-
ments of other TSEs in which longer incubation periods
are obtained for infection via the oral route [31]. Howev-
er, they are similar to recent estimates of the incubation
period for kuru (mean 10–13 years, 90th percentile be-
tween 21 and 27 years [25]).
Discussion
The continued decrease in the annual incidence of vCJD
in the UK has resulted in revised projections which are
considerably lower than in previous years. In particular,
the uncertainty in the potential size of the primary epi-
Figure 2
Likelihood profile for long-term (to 2080) projections of 
future vCJD cases fitting to a) the vCJD case data alone and 
b) to the vCJD case data and prevalence data. The bold line 
shows the cut-off corresponding to the 95% confidence limit 
(based on the maximized log likelihood and one degree of 
freedom). For b), the blue and red lines show the contribu-
tion to the likelihood from the vCJD case data and preva-
lence data respectively.
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demic in the known susceptible genotype (MM-homozy-
gotes) has decreased resulting in narrower prediction
intervals. Our results suggest that the vCJD epidemic will
continue to decline with a best estimate of only 40 future
cases and upper limit of the 95% prediction interval of
500 future cases. Even with the additional fitting of the ap-
pendix data (which estimates a higher prevalence of
asymptomatic infection in the population than would be
predicted by fitting the model to the vCJD case data
alone), the best fitting model estimates just 100 future
cases with an upper limit of the 95% prediction interval of
2,500 cases. These results show a substantial decline in the
worst-case epidemic even compared to one year ago [9],
and indicate that the epidemic now appears to be in de-
cline. The narrower prediction intervals obtained, and in
particular the reduction in the upper 95% prediction in-
terval (from approximately 50,000 based on cases to the
end of 2000 and 7,000 based on cases to the end of 2001)
are due solely to the decline in vCJD cases observed over
the past 2 years and to the stable age distribution of these
cases.
Our analyses relate only to the 40% of the population
known to be genetically susceptible to infection (MM-ho-
mozygotes). To date, there have been no cases of vCJD in
other genotypes and hence it is difficult to make projec-
Figure 3
MLE of the probability density function (PDF) of the incuba-
tion period distribution obtained from fitting to the vCJD 
case data alone and to the vCJD case and prevalence data 
simultaneously.
Figure 4
MLE of the probability density function (PDF) of the age-
dependent susceptibility/exposure function obtained from fit-
ting to the vCJD case data alone and to the vCJD case and 
prevalence data simultaneously.
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Likelihood profile for the mean incubation period. The bold 
lines show the cut-offs corresponding to the 95% confidence 
limits (based on the maximized log likelihood and one degree 
of freedom).
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tions of the scale of any epidemic in the remainder of the
population. Throughout our analyses we have assumed
that the one positive appendix arose from an MM-ho-
mozygous individual. If this is not the case, then the re-
sults from the appendix study could indicate the presence
of infection in other genotypes. Whilst it remains possible
that cases may arise in these other genotypes in the future,
it is unlikely that large epidemics would occur. This is be-
cause these genotypes must either have longer incubation
periods or be less susceptible to infection to have resulted
in no observed cases to date. In the former case, longer in-
cubation periods are likely to result in a lower per-capita
incidence because of the increased probability as they age
that these individuals will die from other causes. In the
latter case, reduced susceptibility will result in a lower per-
capita incidence. The only way in which a large future ep-
idemic could therefore occur is if the vCJD cases diag-
nosed to date are from a very small group of highly
susceptible individuals (defined by a rare, and currently
unknown, genetic marker) and the remainder of the
population are less susceptible but will eventually devel-
op disease. Such a scenario appears unlikely.
The analyses presented here do not provide any indication
of the potential for secondary transmission of the agent,
for example through blood products or via surgical
instruments. Preliminary data from the study of appendix
tissue suggest that the prevalence of asymptomatic infec-
tion may well be significant, although one must be cau-
tious in extrapolating from small samples. Population-
based studies of tonsil tissues are now planned (testing
approximately 50,000 tissues) and a national archive is in
preparation [32]. Although the results of these studies will
provide useful information on the prevalence of late-stage
infection, their interpretation will remain limited by our
relatively poor understanding of the sensitivity and specif-
icity of the diagnostic tests throughout disease incubation.
Furthermore, such studies are necessarily limited in scale
by both the samples available and the limited automation
of the detection process. The development of a diagnostic
test (for example, a blood test) that is able to detect infec-
tion early in the incubation period and that can be used to
reduce the risk of secondary transmission therefore re-
mains a high priority.
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